SCHEDULE: RA Capital Discloses 9% Stake in BetterLife Pharma

RA Capital Management and its affiliates have reported beneficial ownership of 9.0% of BetterLife Pharma Inc.'s common shares, signaling a substantial investment.

Summary

• RA Capital Management, L.P., along with its affiliates Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., have collectively reported beneficial ownership of 55,420,000 common shares of BetterLife Pharma Inc.
• This holding represents 9.0% of the company's outstanding common shares.
• The filing is a Schedule 13G, indicating that the reporting persons are passive investors and do not intend to influence or change control of the issuer.
• The shares were acquired through the RA Capital Healthcare Fund, L.P., with RA Capital Management serving as the investment adviser.
• The total number of outstanding shares used for calculating the percentage ownership includes 170,965,339 shares outstanding as of September 10, 2026, and 447,041,840 shares issued in a public offering that closed on September 15, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant but not overwhelming stake taken by a known investment firm, suggesting confidence in the company's future prospects without immediate aggressive action.

Positives

• A significant investment firm, RA Capital Management, has taken a substantial 9.0% stake in BetterLife Pharma, suggesting confidence in the company's value and future prospects.
• The filing indicates a large number of shares (55,420,000) are held, which could lead to increased liquidity and market interest in the stock.
• The reporting persons are classified as passive investors, implying they are not seeking to control the company, which may be viewed positively by existing management and shareholders.

Negatives

• The filing does not provide specific details on the acquisition cost or the exact timing of the purchases, making it difficult to assess the investment's immediate profitability.
• While a 9.0% stake is significant, it does not represent a controlling interest, meaning the reporting persons may not have the power to enact major strategic changes.

Risks

• The passive nature of the investment means that if the company's performance deteriorates, RA Capital may divest its shares, potentially causing downward pressure on the stock price.
• Future actions by RA Capital, such as increasing their stake or becoming more active, could lead to increased volatility.
• The substantial number of shares held by a single entity could be subject to lock-up periods or other restrictions not detailed in this filing, impacting their ability to sell.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from BetterLife Pharma Inc. However, the substantial investment by RA Capital Management may imply a positive outlook from the investment firm regarding the company's future performance.

Management Comments

• RA Capital Management, L.P. serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund.
• The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the common shares of the Issuer reported herein.
• Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act.
• As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Industry Context

StockSavvy.ai notes that significant stake-building by specialized healthcare investment funds like RA Capital often precedes major corporate developments, such as strategic partnerships, pipeline advancements, or M&A activity within the biotechnology and pharmaceutical sectors. This filing suggests RA Capital sees potential value or strategic opportunity in BetterLife Pharma.

Stakeholder Impact

• Shareholders: May view the investment by a reputable firm as a positive signal, potentially increasing confidence and market interest. However, it also introduces a significant holder whose future actions could influence share price.
• Management: May see the investment as validation, but also as increased scrutiny. The passive nature of the filing suggests no immediate pressure for control changes.
• Creditors/Suppliers: A stable or growing share price, potentially supported by institutional interest, could be viewed positively for the company's financial stability.

Next Steps

• Monitor future filings from RA Capital Management for any changes in their stake or investment strategy.
• Observe BetterLife Pharma Inc.'s corporate announcements for any strategic shifts or developments that may have prompted RA Capital's investment.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the significant stake taken by RA Capital suggests potential upside and confidence in BetterLife Pharma, the filing is purely a disclosure of passive ownership. Without further information on the company's performance, strategy, or RA Capital's specific intentions beyond passive investment, a 'hold' allows investors to await more concrete developments before making a buy or sell decision.

Keywords

BetterLife Pharma, RA Capital Management, Schedule 13G, Beneficial Ownership, Healthcare Fund, Investment Adviser, Common Shares, Securities Exchange Act